Long-term benefits of omalizumab in a patient with severe non-allergic asthma

Francesco Menzella, Roberto Piro, Nicola Facciolongo, Claudia Castagnetti, Anna Simonazzi, Luigi Zucchi

Research output: Contribution to journalArticlepeer-review


Introduction: Currently, omalizumab is indicated for the treatment of patients with severe allergic uncontrolled asthma despite optimal therapy.Case presentation: We studied a 52-year-old man who has been suffering from severe non allergic steroid-resistant asthma with increased levels of total IgE and a lot of comorbidity. After a 3 years long treatment with omalizumab, he presented a significant improvement in disease control in terms of hospitalizations, exacerbation, quality of life and lung function with good safety profile.Conclusion: Our case shows, after a long follow-up, how omalizumab can be effective in a severe form of non-atopic asthma. It is therefore hoped that further studies can identify indicators that are able to give to clinicians information about patients who can be responsive to monoclonal anti-IgE antibody even if non allergic.

Original languageEnglish
Article number9
JournalAllergy, Asthma and Clinical Immunology
Issue number1
Publication statusPublished - May 24 2011

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine
  • Immunology


Dive into the research topics of 'Long-term benefits of omalizumab in a patient with severe non-allergic asthma'. Together they form a unique fingerprint.

Cite this